Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 10
Submit an article Journal homepage
103
Views
22
CrossRef citations to date
0
Altmetric
Review

Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor

Kurt Vermeire Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. [email protected]
&
Dominique Schols Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. [email protected]
Pages 1199-1212 | Published online: 27 Sep 2005

Bibliography

  • DE CLERCQ E: Emerging anti-HIV drugs. Expert Opin. on Emerging Drugs (2005) 10(2):241–273.
  • ••An excellent review on antiviral agentstargeting different steps of HIV infection.
  • RICHMAN DD: HIV chemotherapy. Nature (2001) 410:995–1001.
  • BLANKSON JN, PERSAUD D, SILICIANO RF: The challenge of viral reservoirs in HIV-1 infection. Ann. Rev Med. (2002) 53:557–593.
  • CHUN TW, FAUCI AS: Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Nati Acad. Sci. USA (1999) 96:10958–10961.
  • DALGLEISH AG, BEVERLEY PC, CLAPHAM PR, CRAWFORD DH, GREAVES MF, WEISS RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1984) 312:763–767.
  • ••A pivotal paper describing the discovery ofCD4 as the main receptor for HIV.
  • FENG Y, BRODER CC, KENNEDY PE, BERGER EA: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 272:872–877.
  • TRKOLA A, DRAGIC T, ARTHOS J et al.: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (1996) 384:184–187.
  • WU L, GERARD NP, WYATT R et al.: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 384:179–183.
  • ALKHATIB G, COMBADIERE C, BRODER CC et al: CC CKR5: RANTES, MIP-la, MIP-113 receptor as a cofactor for macrophage-tropicHIV-1. Science (1996) 272:1955-1958..DENG H, LIU R, ELLMEIER W et al: of a major co-receptor for primary isolates of HIV-1. Nature (1996) 381:661–666.
  • BERSON JF, LONG D, DORANZ BJ, RUCKER J, JIRIK FR, DOMS RW: A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus Type 1 strains.' Viral. (1996) 70:6288–6295.
  • CONNOR RI, SHERIDAN KE, CERADINI D, CHOE S, LANDAU NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. I Exp. Med. (1997) 185:621–628.
  • HOFFMAN TL, LABRANCHE CC, ZHANG W et al: Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. USA (1999) 96:6359–6364.
  • COCCHI F, DEVICO AL, GARZINO-DEMO A, CARA A, RC, LUSSO P: The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. (1996) 2:1244–1247.
  • CHAN DC, FASS D, BERGER JM, KIM PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 89:263–273.
  • WEISSENHORN W, DESSEN A, HARRISON SC, SKEHEL JJ, WILEY DC: Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 387:426–430.
  • DOMS RW: Beyond receptor expression:the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology (2000) 276:229–237.
  • LITTMAN DR: The structure of the CD4and CD8 genes. Ann. Rev Inununol. (1987) 5:561–584.
  • KRUISBEEK AM, MOND JJ, FOWLKES BJ, CARMEN JA, S, LONGO DL: Absence of the Lyt-2-,L3T4* lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function.. Exp. Med. (1985) 161:1029–1047.
  • LAMARRE D, CAPON DJ, KARP DR, GREGORY T, LONG E0, SEKALY RP: Class II MHC molecules and the HIV gp 120 envelope protein interact with distinct regions of the CD4 molecule. EMBO J. (1989) 8:3271–3277.
  • RUDD CE, TREVILLYAN JM, DASGUPTA JD, WONG LL, SCHLOSSMAN SF: The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human lymphocytes. Proc. Natl. Acad. Li. USA(1988) 85:5190–5194.
  • LEAHY DJ: A structural view of CD4 and CD8. FASEB J. (1995) 9:17–25.
  • •A review on the structure of the CD4 receptor.
  • WANG JH, YAN YW, GARRETT TP et al: Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature (1990) 348:411–418.
  • RYU SE, KWONGPD, TRUNEH A et al: Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature (1990) 348:419–426.
  • CHAO BH, COSTOPOULOS DS, CURIEL T et al: A 113-amino acid fragment of CD4 produced in Escherichia coli blocks human immunodeficiency virus-induced cell fusion. Biol. Chem. (1989) 264:5812–5817.
  • ARTHOS J, DEEN KC, CHAIKIN MA et al: Identification of the residues in CD4 critical for the binding of HIV. Cell (1989) 57:469–481.
  • SATTENTAU QJ, DALGLEISH AG, WEISS RA, BEVERLEY PC: Epitopes of the CD4 antigen and HIV infection. Science (1986) 234:1120–1123.
  • JAMESON BA, RAO PE, KONG LI et al:Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein. Science (1988) 240:1335–1339.
  • ASHKENAZI A, PRESTA LG, MARSTERS SA et al: Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis. Proc. Nail Acad. Sci. USA (1990) 87:7150–7154.
  • CLAYTON LK, SIEH M, PIOUS DA, REINHERZ EL: Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding. Nature (1989) 339:548–551.
  • MIZUKAMI T, FUERST TR, EA, MOSS B: Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis. Proc. Nati Acad. ScL USA (1988) 85:9273–9277.
  • MOEBIUS U, CLAYTON LK, ABRAHAM S, HARRISON SC, REINHERZ EL: The human immunodeficiency virus gp120 binding site on CD4: delineation by quantitative equilibrium and kinetic binding studies of mutants in conjunction with a high-resolution CD4 atomic structure. J. Exp. Med. (1992) 176:507–517.
  • •An excellent paper describing the importance of Phe43 in the gp120 binding site on CD4.
  • RICHARDSON NE, BROWN NR, HUSSEY RE et al.: Binding site for human immunodeficiency virus coat protein gp120 is located in the NH2-terminal region of T4 (CD4) and requires the intact variable-region-like domain. Proc. Nati Acad. ScL USA (1988) 85:6102–6106.
  • KWONG PD, WYATT R, ROBINSON J, SWEET RW, SODROSKI J, HENDRICKSON WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 393:648–659.
  • KWONG PD, WYATT R, QJ, SODROSKI J, HENDRICKSON WA: Oligomeric modeling and electrostatic analysis of the120 envelope glycoprotein of human immunodeficiency virus. J. Viral. (2000) 74:1961–1972.
  • CHEN B, VOGAN EM, GONG H, SKEHEL JJ, WILEY DC, SC: Structure of an unliganded simian immunodeficiency virus gp120 core. Nature (2005) 433:834–841.
  • MURRAY JL, HU QX, NAVENOT JM, PEIPER SC: Role of CD4 hinge region in GP120 utilization by immunoglobulin domain 1. Biochem. Biophys. Res. Commun. (2002) 292:449–455.
  • WU H, KWONG PD, HENDRICKSON WA: Dimeric association and segmental variability in the structure of human CD4. Nature (1997) 387:527–530.
  • POULIN L, EVANS LA, TANG SB et al.:Several CD4 domains can play a role in human immunodeficiency virus infection in cells." Viral. (1991) 65:4893–4901.
  • GOLDING H, BLUMENTHAL R, MANISCHEWITZ J, LITTMAN DR, DIMITROV DS: Cell fusion mediated by interaction of a hybrid CD4.CD8 molecule with the human immunodeficiency virus Type 1 envelope glycoprotein does occur after a long lag time. J. Viral. (1993) 67:6469–6475.
  • BRADY RL, DODSON EJ, GG et al: Crystal structure of domains 3 and 4 of rat CD4: relation to the NH2-terminal domains. Science (1993) 260:979–983.
  • MOIR S, PERREAULT J, POULIN L: Postbinding events mediated by human immunodeficiency virus Type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4. Viral. (1996) 70:8019–8028.
  • YACHOU A, SEKALY RP: Binding of soluble recombinant HIV envelope glycoprotein, rgp120, induces conformational changes in the cellular membrane-anchored CD4 molecule. Biochem. Biophys. Res. Commun. (1999) 265:428–433.
  • MYSZKA DG, SWEET RW, HENSLEY P et al: Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. USA (2000) 97:9026–9031.
  • KWONG PD, WYATT R, MAJEED S et al.: Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure Fold. Des. (2000) 8:1329–1339.
  • WYATT R, KWONG PD, DESJARDINS E et al.: The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 393:705–711.
  • WYATT R, SODROSKI J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 280: 1884-1888.
  • SMITH DH, BYRN RA, MARSTERS SA, GREGORY T, GROOPMAN JE, DJ: Blocking of HIV-1 infectivity a soluble, secreted form of the CD4 antigen. Science (1987) 238: 1704-1707.
  • TRAUNECKER A, LUKE W, KARJALAINEN K: Soluble CD4 molecules neutralize human immunodeficiency virus Type 1. Nature (1988) 331:84–86.
  • DEEN KC, McDOUGAL JS, R et al: A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature (1988) 331:82–84.
  • SCHOOLEY RT, MERIGAN TC, GAUT P et al.: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A Phase I-II escalating dosage trial. Ann. Intern. Med. (1990) 112:247–253.
  • DAAR ES, LI XL, MOUDGIL T, HO DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus Type 1 isolates. Proc. Natl. Acad. ScL USA (1990) 87:6574–6578.
  • MOORE JP, MCKEATING JA, HUANG YX, ASHKENAZI A, HO DD: Virions of primary human immunodeficiency virus Type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J. Vim]. (1992) 66:235–243.
  • ORLOFF SL, KENNEDY MS, BELPERRON AA, MADDON PJ, McDOUGAL JS: Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus Type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced to sCD4.Viral. (1993)67:1461–1471.
  • SULLIVAN N, SUN Y, SATTENTAU Q et al.: CD4-Induced conformational changes in the human immunodeficiency virus Type 1 gp120 glycoprotein: consequences for virus entry and. J. Virol (1998) 72:4694–4703.
  • SALZWEDEL K, SMITH ED, DEY B, BERGER EA: Sequential CD4-coreceptor interactions in human immunodeficiency virus Type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. Virol (2000) 74:326–333.
  • ALLAWAY GP, DAVIS-BRUNO KL, BEAUDRY GA et al.: Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV Type 1 isolates. AIDS Res.. Retroviruses (1995) 11:533–539.
  • GAUDUIN MC, ALLAWAY GP, MADDON PJ, BARBAS CF III, BURTON DR, KOUP RA: Effective ex vivo neutralization of human immunodeficiency virus Type 1 in plasma by recombinant immunoglobulin molecules. J. Virol (1996) 70:2586–2592.
  • TRKOLA A, POMALES AB, YUAN H et al.: Cross-clade neutralization of primary isolates of human immunodeficiency virus Type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Virol (1995) 69:6609–6617.
  • KETAS TJ, FRANK I, KLASSE PJ et al:Human immunodeficiency virus Type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells." Virol (2003) 77:2762–2767.
  • NAGASHIMA KA, THOMPSON DA, ROSENFIELD SI, MADDON PJ, DRAGIC T, OLSON WC: Human immunodeficiency virus Type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion." Infect. Dis. (2001) 183:1121–1125.
  • GAUDUIN MC, ALLAWAY GP, OLSON WC, WEIR R, MADDON PJ, KOUP RA: CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus Type 1 isolates. (1998) 72:3475-3478.
  • TRKOLA A, KETAS T, VN etal: Neutralization sensitivity of human immunodeficiency virus Type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage." Virol (1998) 72:1876–1885.
  • JACOBSON JM, LOWY I, CV et al.: Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) Type 1 entry inhibitor PRO 542 in HIV-infected adults. J. Infect. Dis. (2000) 182:326–329.
  • SHEARER WT, ISRAEL RJ, STARR S et al.: Recombinant CD4-IgG2 in human immunodeficiency virus Type 1-infected children: Phase 1/2 study. j Infect. Dis. (2000) 182:1774–1779.
  • JACOBSON JM, ISRAEL RJ, LOWY I et al.: Treatment of advanced human immunodeficiency virus Type 1 disease with the viral entry inhibitor PRO 542. Antimicrob. Agents Chemother. (2004) 48:423–429.
  • DEY B, DEL CASTILLO CS, EA: Neutralization of human immunodeficiency virus Type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. Virol (2003) 77:2859–2865.
  • MARTIN L, STRICHER F, MISSED et al.: Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol (2003) 21:71–76.
  • VITA C, DRAKOPOULOU E, J et al.: Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA (1999) 96:13091–13096.
  • LI H, SONG H, HEREDIA A et al: Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein. Biocorgug. Chem. (2004) 15:783–789.
  • WANG T, ZHANG Z, WALLACE OB et al.: Discovery of 4-benzoy1-1-[(4-methoxy-1H- pyrrolor2,3-blpyridin-3-y6oxoacetyll-2- (A)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. (2003) 46:4236–4239.
  • LIN PF, BLAIR W, WANG T et al.: A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Nati Acad. Sci. USA (2003) 100(19):11013–11018.
  • GUO Q, HO HT, DICKER I et al.: Biochemical and genetic characterizations of a novel human immunodeficiency virus Type 1 inhibitor that blocks gp120-CD4. Virol (2003) 77(19):10528–10536.
  • WANG HG, WILLIAMS RE, LIN PF: A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding. Curr. Pharm. Des. (2004) 10:1785–1793.
  • MOORE PL, CILLIERS T, MORRIS L: Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. AIDS (2004) 18:2327–2330.
  • SI Z, MADANI N, COX JM et al: Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Nati Acad. Sci. USA (2004) 101:5036–5041.
  • MADANI N, PERDIGOTO AL, VA SAN K et al: Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155.. (2004) 78:3742–3752.
  • LIN PF, HO HT, GONG YF et al.: Characterization of a small molecule HIV-1 attachment inhibitor BMS-488043: virology, resistance and mechanism of action. I I th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA (2004) A-534 (Abstract).
  • HANNA G, YAN J-H, FISKE W, MASTERSON T, ZHANG D, GRASELA D: Safety, tolerability, and pharmacokinetics of a novel, small-molecule HIV-1 attachment inhibitor, BMS-488043, after single and multiple oral doses in healthy subjects. 11th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA (2004):A-535 (Abstract).
  • HANNA G, LALEZARI JP, J et al.: Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1 infected subjects. I I th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA (2004) A-141 (Abstract).
  • BOYD MR, GUSTAFSON KR, McMAHON JB et al.: Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.. Agents Chemother. (1997) 41:1521–1530.
  • TSAI CC, EMAU P, JIANG Yet al.: Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res. Hum. Retroviruses (2003) 19(7):535–541.
  • TSAI CC, EMAU P, JIANG Y et al: Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses (2004) 20:11–18.
  • COLLELUORI DM, TIEN D, KANG F et al: Expression, purification, and characterization of recombinant cyanovirin-N for vaginal anti-HIV microbicide development. Expr. PuriE (2005) 39:229–236.
  • DEY B, LERNER DL, LUSSO P, BOYD MR, ELDER JH, BERGER EA: Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus Type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J. Virol. (2000) 74:4562–4569.
  • ESSER MT, MORI T, MONDOR I et al:Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus Type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. Virol. (1999) 73:4360–4371.
  • MORI T, BOYD MR: Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob. Agents Chemother. (2001) 45:664–672.
  • SHENOY SR,'KEEFE BR, BOLMSTEDT AJ, CARTNER LK, BOYD MR: Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. ./. Pharmacol.. Ther. (2001) 297:704–710.
  • BARRIENTOS LG, LOUIS JM, RATNER DM, SEEBERGER PH, GRONENBORN AM: Solution structure of a circular-permuted variant of the potent HIV-inactivating protein cyanovirin-N: structural basis for protein stability and interaction. J. Mol. Biol.(2003) 325:211–223.
  • WITVROUW M, FIKKERT V, HANTSON A et al.: Resistance of human immunodeficiency virus Type 1 to the high-mannose binding agents cyanovirin N and concanavalin A." Virol. (2005) 79:7777–7784.
  • GIOMARELLI B, PROVVEDI R, MEACCI F et al.: The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS (2002) 16:1351–1356.
  • BALZARINI J, SCHOLS D, NEYTS J, VAN DAMME E, PEUMANS W, DE CLERCQ E: a-(1-3)- and a-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. Antimicrob. Agents Chemother. (1991) 35:410–416.
  • BALZARINI J, HATSE S, VERMEIRE K-specific plant lectins fromthe Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob. Agents Chemother. (2004) 48:3858–3870.
  • •An interesting report on the potential of plant lectins as microbicides.
  • BALZARINI J, VAN LAETHEM K, HATSE S et al: Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. I Virol. (2004) 78:10617–10627.
  • BALZARINI J, VAN LAETHEM K, HATSE S et al.: Marked Depletion of Glycosylation Sites in HIV-1 gp120 under Selection Pressure by the Mannose-Specific Plant Lectins of Hippeastrum Hybrid and Galanthus nivalis. Mol. Pharm. (2005) 67:1556–1565.
  • BURTON DR, PYATI J, KODURI R et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 266:1024–1027.
  • BURTON DR, BARBAS CF III, PERSSON MA, KOENIG S, CHANOCK RM, LERNER RA: A large array of human monoclonal antibodies to Type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl. Acad. Li. USA (1991) 88:10134–10137.
  • ROBEN P, MOORE JP, THALI M, SODROSKI J, BARBAS CF III, BURTON DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus Type if f Virol. (1994) 68:4821–4828.
  • ZWICK MB, PARREN PW, E0 et al: Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus Type 1 gp120.. (2003) 77:5863–5876.
  • BURES R, MORRIS L, WILLIAMSON C et al.: Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus Type 1 from South Africa. J. Virol. (2002) 76:2233–2244.
  • PARREN PW, MARX PA, HESSELL AJ et al.: Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.j Virol. (2001) 75:8340–8347.
  • BURKLY LC, OLSON D, SHAPIRO R et al.: Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion.' Immunol. (1992) 149:1779–1787.
  • BURKLY L, MULREY N, R, DIMITROV DS: Synergistic inhibition of human immunodeficiency virus Type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gp120 antibodies.. (1995) 69:4267–4273.
  • MOORE JP, SATTENTAU QJ, PJ, BURKLY LC: A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus Type 1 (HIV-1) and HIV-1 infection of CD4' cells. J. Virol. (1992) 66:4784–4793.
  • REIMANN KA, LIN W, BIXLER S et al: A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res. Hum. Retroviruses (1997) 13:933–943.
  • REIMANN KA, BURKLY LC, BURRUS B, WAITE BC, LORD CI, NL: In vivo administration to rhesus monkeys of a CD4-specific monoclonal antibody capable of blocking AIDS virus replication. AIDS Res. Hum. Retroviruses (1993) 9:199–207.
  • REIMANN KA, KHUNKHUN R, UN W, GORDON W, FUNG M: A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res. Hum. Retroviruses (2002) 18(11):747–755.
  • BOON L, HOLLAND B, GORDON W et al.: Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology (2002) 172:191–203.
  • KURITZKES DR, JACOBSON J, POWDERLY WG et al: Antiretroviral Activity of the Anti-CD4 Monoclonal Antibody TNX-355 in Patients Infected with HIV Type 1. J. Infect. Dis. (2004) 189:286–291.
  • ••Proof-of-concept study in HIV-1-infectedpatients demonstrating the feasibility of targeting the cellular CD4 receptor as a potential treatment approach to HIV.
  • JACOBSON JM, KURITZKES DR, GODOFSKY E et al.: Phase lb study of the anti-CD4 monoclonal antibody TNX-355 in HIV-1 infected subjects: safety and antiretroviral activity of multiple doses. I I th Conference on Retro viruses and Opportunistic Infections. San Francisco, CA, USA (2004):A-536 (Abstract).
  • RUSCONI S, MOONIS M, DP et al.: Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob. Agents Chemother. (1996) 40:234–236.
  • DEZZUTTI CS, JAMES VN, RAMOS A et al.: In vitro comparison of topical microbicides for prevention of human immunodeficiency virus Type 1 transmission. Antimicrob. Agents Chemother. (2004) 48:3834–3844.
  • GREENHEAD P, HAYES P, WATTS PS, LAING KG, GRIFFIN GE, RJ: Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. ./. Viral. (2000) 74:5577–5586.
  • WEBER J, NUNN A, O'CONNOR T et al: 'Chemical condoms' for the prevention of HIV infection: evaluation of agents against SHIV89.6PD in vitro and in vivo. AIDS (2001) 15:1563–1568.
  • MILLIGAN GN, CHU CE YOUNG CG, STANBERRY LR: Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4' and CD8' T lymphocytes. Biol. Reprod. (2004) 71:1638–1645.
  • VAN DAMME L, WRIGHT A, K et al.: A Phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex. Transm. Infect. (2000) 76:126–130.
  • TABET SR, CALLAHAN MM, CK et al.: Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J. Acquir Immune Defic. Syndr. (2003) 33(4):476–483.
  • MAYER KH, KARIM SA, KELLY C et al.: Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS (2003) 17:321–329.
  • KELLER M, ZERHOUNI-LAYACHI B, CHESHENKO N et al: The candidate topical microbicide PRO 2000/5 inhibits HIV and HSV infection following vaginal application: results of a double-blind placebo-controlled trial. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2005):A-535 (Abstract).
  • YANG QE, STEPHEN AG, JW et al: Discovery of small-molecule human immunodeficiency virus Type 1 entry inhibitors that target the gp120-binding domain of CD4. Virol (2005) 79:6122–6133.
  • HOXIE JA, MATTHEWS DM, CALLAHAN KJ, CASSEL DL, COOPER RA: Transient modulation and internalization of T4 antigen induced by phorbol esters. J. Immunol (1986) 137(4):1194–1201.
  • ACRES RB, CONLON PJ, DY, GALLIS B: Rapid phosphorylation and modulation of the T4 antigen on cloned helper T cells induced by phorbol myristate acetate or antigen. ./. Biol. Chem. (1986) 261(34):16210–16214.
  • PELCHEN-MATTHEWS A, IJ, MARSH M: Phorbol ester-induced downregulation of CD4 is a multistep process involving dissociation from p56", increased association with-coated pits, and altered endosomal sorting. I Exp. Med. (1993) 178:1209–1222.
  • FIRESTEIN GS, REIFLER D, D, GRUBER HE: Rapid and reversible modulation of T4 (CD4) on monocytoid cells by phorbol myristate acetate: effect on HIV susceptibility. (1988) 113:63-69.
  • GOLDING H, MANISCHEWITZ J, VUJCIC L, BLUMENTHAL R, DIMITROV DS: The phorbol ester phorbol myristate acetate inhibits human immunodeficiency virus Type 1 envelope-mediated fusion by modulating an accessory component(s) in CD4-expressing cells. J. Viral. (1994) 68(3):1962–1969.
  • RABANAL M, FRANCH A, NOE V et al.: CD4 expression decrease by antisense oligonucleotides: inhibition of rat T CD4* cell reactivity. Oligonucleotides (2003) 13:217–228.
  • NOVINA CD, MURRAY ME DM etal: siRNA-directed inhibition of HIV-1 infection. Nat. Med. (2002) 8:681–686.
  • McMANUS MT, HAINES BB, CP et al: Small interfering RNA-mediated gene silencing in T lymphocytes. (2002) 169:5754–5760.
  • VERMEIRE K, SCHOLS D, BELL TW: CD4 down-modulating compounds with potent anti-HIV activity. Curl: Pharm. Des. (2004) 10:1795–1803.
  • VERMEIRE K, ZHANG Y, PRINCEN K et al: CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology (2002) 302:342–353.
  • ••Discovery of a specific CD4 down-modulator with potent anti-HIV activity.
  • VERMEIRE K, PRINCEN K, HATSE S et al: CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS (2004) 18:2115–2125.
  • VERMEIRE K, SCHOLS D: Specific CD4 down-modulating compounds with potent anti-HIV activity. J. Leukoc. Biol. (2003) 74:667–675.
  • VERMEIRE K, BELL TW, CHOI HJ et al: The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol. Pharm. (2003) 63:203–210.
  • VERMEIRE K, VAN LAETHEM K, VANDAMME AM, BELL TW, DE CLERCQ E, SCHOLS D: Resistance profile of human immunodeficiency virus to CADA, a novel HIV inhibitor that targets the cellular CD4 receptor. Antiviral Res. (2005) 65(3):A43.
  • EDWARDS TG, HOFFMAN TL, BARIBAUD F et al.: Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus Type 1 envelope protein. J. Viral. (2001) 75:5230–5239.
  • KOLCHINSKY P, KIPRILOV E, SODROSKI J: Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Viral. (2001) 75:2041–2050.
  • RAHEMTULLA A, FUNG-LEUNG WP, SCHILHAM MW et al.: Normal development and function of CD8* cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 353:180–184.
  • RAHEMTULLA A, KUNDIG TM, NARENDRAN A et al: Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice. Eur. Inllnunol. (1994) 24:2213–2218.
  • LOCKSLEY RM, REINER SL, HATAM F, LITTMAN DR, KILLEEN N: Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice. Science (1993) 261:1448–1451.
  • ZHENG B, OZEN ZZ, CAO S, ZHANG Y, HAN S: CD4-deficient T helper cells are capable of supporting somatic hypermutation and affinity maturation of germinal center B cells. Eur. Inllnunol. (2002) 32:3315–3325.
  • VIDAL K, DANIEL C, HILL M, LITTMAN DR, ALLEN PM: Differential requirements for CD4 in TCR-ligand interactions. Immune]. (1999) 163:4811–4818.
  • LAYNE SP, MERGES MJ, DEMBO M, SPOUGE JL, NARA PL: HIV requires multiple gp120 molecules for CD4-mediated infection. Nature (1990) 346:277–279.
  • VERMEIRE K, SCHOLS D: Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs. Antlinicrob. Chernother. (2005) 56:270–272.

Websites

  • http://www.unaids.org/en/resources/ epidemiology.asp/ Provides current information on the AIDS epidemic worldwide.
  • http://www.tanox.com/ current information on TNX-355.
  • http://www.indevus.com/ current information on PRO 2000.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.